- 1 Full title: The effect of smoking on multiple sclerosis: a mendelian randomization study
- 2 Short title: Smoking exposure and risk multiple sclerosis
- 3 Ruth E Mitchell^{1,2*}, Kirsty Bates^{2*}, Robyn E Wootton^{1,3,4}, Adil Harroud^{6,7}, J. Brent
- 4 Richards^{8,9,10,11,12}, George Davey Smith^{1,2}, Marcus R Munafò^{1,4,5}
- 5 1. Medical Research Council Integrative Epidemiology Unit, University of Bristol, Oakfield
- 6 House, Oakfield Grove, Bristol BS8 2BN, UK
- 7 2. Population Health Sciences, Bristol Medical School, University of Bristol, UK
- 8 3. Avon & Wiltshire Mental Health Partnership Trust, UK
- 9 4. School of Psychological Science, University of Bristol, Bristol BS8 1TU, UK
- 10 5. NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation
- 11 Trust and the University of Bristol, BS8 2BN
- 12 6. Department of Neurology, University of California San Francisco, CA, USA
- 13 7. Weill Institute for Neurosciences, University of California San Francisco, CA, USA
- 14 8. Department of Human Genetics, McGill University, Montreal, Quebec, Canada
- 15 9. Centre for Clinical Epidemiology, Department of Epidemiology, Lady Davis Institute for
- 16 Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
- 17 10. Department of Medicine, McGill University Montreal, Quebec, Canada
- 18 11. Department of Human Genetics, McGill University, Montreal, Quebec, Canada
- 19 12. Department of Twin Research and Genetic Epidemiology, King's College London, UK
- 20 *These authors contributed equally
- 21 Correspondence should be addressed to Ruth Mitchell (email: <u>r.mitchell@bristol.ac.uk</u>).

22 Abstract

23	The causes of multiple sclerosis (MS) remain unknown. Smoking has been associated with
24	MS in observational studies and is often thought of as an environmental risk factor. We used
25	two-sample Mendelian Randomization (MR) to examined whether this association is causal
26	using genetic variants identified in genome-wide association studies (GWAS) as associated
27	with smoking. We assessed both smoking initiation and lifetime smoking behaviour (which
28	captures smoking duration, heaviness and cessation). There was very limited evidence for a
29	meaningful effect of smoking on MS susceptibility was measured using summary statistics
30	from the International Multiple Sclerosis Genetics Consortium (IMSGC) meta-analysis,
31	including 14,802 cases and 26,703 controls. There was no clear evidence for an effect of
32	smoking on the risk of developing MS (smoking initiation: odds ratio [OR] 1.03, 95%
33	confidence interval [CI] 0.92-1.61; lifetime smoking: OR 1.10, 95% CI 0.87-1.40). These
34	findings suggest that smoking does not have a detrimental consequence on MS susceptibility.
35	Further work is needed to determine the causal effect of smoking on MS progression.

36

37 Background

38 Smoking is an avoidable environmental cause to many life-threatening diseases such as lung 39 cancer, heart and respiratory disorders (1,2). There is emerging evidence linking cigarette 40 smoke to conditions negatively affecting the central nervous system (CNS), like multiple 41 sclerosis (MS) (3,4). MS is a chronic neurological disorder causing autoimmune breakdown 42 of the myelin sheath surrounding axons in the CNS (5). The disease is characterised by 43 periods of disease activity followed by remission and/or progressive neurological decline, 44 resulting in increasing disability (6). Like most autoimmune conditions, there is no known 45 specific cause; however, we know there is an interaction between genetic and environmental

46	factors in susceptible individuals, that go on to develop the disorder (7). Unfortunately, there
47	is no cure for MS(8), and people diagnosed often live with extreme disability (9). There are
48	emerging treatments aimed at modifying the disease course (10), but they are not universally
49	effective particularly with regards to the progressive form of the disease. Therefore, it is
50	important to continue targeting prevention by means of establishing causal links.
51	Evidence from observational epidemiological studies suggests that smoking increases MS
52	risk (11). It is hypothesised from experimental studies that exposure to chemicals in cigarette
53	smoke alter the immune cell balance in the lung (12,13) which in turn can lead to generalised
54	pro-inflammatory effects that trigger autoimmunity (14,15), in genetically susceptible
55	individuals (16,17). In addition, cigarette chemicals contribute mechanistically to MS
56	pathobiology. Specifically, nicotine increases the permeability of the blood-brain barrier (18);
57	cyanide contributes to demyelination (19); and nitric oxide causes degeneration of axons
58	(20). There is evidence for an association between smoking and worsening symptoms,
59	number of relapses, lesion load on MRI, brain atrophy rate (15) and the rapidity of disability
60	progression in MS patients (4,21,22).
61	However, it is hard to make causal inferences from observational studies which can be biased
62	by issues of reverse causation and residual confounding. One method which can be used to
63	reduce these sources of bias is Mendelian Randomization (MR) (23). MR can be
64	implemented through instrumental variable analysis that uses genetic variants to proxy the
65	exposure (e.g, smoking) and estimate a causal effect of that exposure on the outcome (e.g,
66	MS). The MR method makes three important assumptions: 1) the genetic variants must
67	robustly predict the exposure, 2) the genetic variants must not be associated with any
68	confounders and 3) the genetic variants must only affect the outcome through the exposure
69	(24). To satisfy the first assumption we selected the most recently available genetic
70	instruments from previously conducted genome-wide association studies (GWAS) associated

71	with smoking behaviour (smoking initiation (25) and lifetime smoking (26)) that can be
72	implemented in a two-sample MR context (Fig 1). The latter two assumptions can be violated
73	by horizontal pleiotropy which occurs when the genetic variants affect the outcome other
74	than through the exposure. We test for this possibility using multiple sensitivity analyses.
75	Fig 1. Directed acyclic graph of the Mendelian randomization framework investigating
76	the causal relationship between smoking and multiple sclerosis. Instrumental variable
77	assumptions: IV1: the instruments must be associated with the exposure; IV2: the instruments
78	must influence MS only through smoking; IV3: the instruments must not associate with
79	measured or unmeasured confounders in the smoking to MS relationship.

80 **Results**

81 Smoking initiation

82 The inverse-variance weighted MR estimate (OR 1.03, 95% confidence interval (CI) 0.92 -83 1.16) revealed no strong evidence for a causal effect of the genetic risk of smoking initiation 84 on incidence of MS (Fig 3). This was consistent across all MR methods employed, providing 85 further support for the result as each MR method has different assumptions and therefore tests 86 for different violations of those assumptions. Indeed, the weighted median and weighted 87 mode only allow SNPs in the largest homogeneous cluster to contribute to the overall 88 estimate and provide estimates with confidence intervals overlapping the null (Fig 3 and 89 Supplementary Fig 1). The 371 SNPs used as genetic proxies for smoking initiation (Fig 2a 90 and Supplementary Table 1) had an F statistic of 44.90 indicating a strong instrument and that 91 weak instrument bias was unlikely to be influencing the effect estimates. There was evidence of heterogeneity with a large Cochran's Q statistic of 559.48, p=6.65x10⁻⁶ and the MR-92 93 PRESSO global test value of 562.12, p<0.000125. However, this not indicative of directional horizontal pleiotropy given the consistent MR Egger estimate (OR 1.13, 95% CI 0.67 to 94

95 1.91), small intercept (0.0017, p=0.73) and symmetrical funnel plot (Supplementary Fig 2). 96 Similarly, MR-RAPS is robust to systematic and idiosyncratic pleiotropy, accounting for 97 weak instruments, pleiotropy and extreme outliers, and gave a similar causal estimate (OR 98 1.05, 95% CI 0.93 to 1.17). Furthermore, MR-PRESSO removes individual SNPs that 99 contribute to heterogeneity disproportionately more than expected in order to reduce 100 heterogeneity. The MR-PRESSO outlier corrected causal estimate was 1.040 (95% CI 1.040 101 to 1.041). Therefore, the second IV assumption (known as the exclusion restriction 102 assumption) of MR has not been violated and directional pleiotropy is unlikely to be biasing 103 the estimates, even though the outlier removal automatically leads to over precise estimates. 104 Leave-one-out and single SNP analyses (Supplementary Fig 3 and 4) were conducted as 105 sensitivity tests sequentially omitting one SNP at a time and performing MR using a single 106 SNP respectively to assess the sensitivity of the results to individual variants. These indicated 107 that there is not a single SNP driving the association whose effect is being masked in the 108 overall analysis. The exclusion of exposure variants located within the MHC did not alter the 109 null association between smoking initiation and incidence of MS (Supplementary Table 2). 110 Fig 2. Flowchart for selection of genetic variants associated with smoking initiation (A) 111 and lifetime smoking (B). Abbreviations: GSCAN: GWAS & Sequencing Consortium of 112 Alcohol and Nicotine use; GWAS: Genome-Wide Association Study; LD: Linkage

113 Disequilibrium; MS: multiple sclerosis; IMSGC: International Multiple Sclerosis Genetics

114 Consortium; MR: Mendelian Randomization; SNP: Single-Nucleotide Polymorphism.

115 Fig 3: Two-sample Mendelian Randomization estimates of the association between

smoking initiation and incidence of multiple sclerosis. Odds ratios are expressed per unit

117 increase in log odds of ever smoking regularly (smoking initiation). MR: Mendelian

118 Randomization; OR=Odds Ratio; CI=Confidence Intervals; p.val: p value.

119 Lifetime smoking

120 There was no clear evidence for a causal effect of the genetic risk of lifetime smoking on 121 incidence of MS (Fig 4). The 125 SNPs used as genetic proxies for lifetime smoking (Fig 2b 122 and Supplementary Table 3) had an F statistic of 44.05 indicating a strong instrument that is 123 unlikely to cause the effect estimates to be affected by weak instrument bias. The inverse-124 variance weighted MR analysis estimate (OR 1.10, 95% CI 0.87 to 1.40) revealed no strong 125 evidence for a causal effect of the genetic risk of lifetime smoking on incidence of MS and 126 was consistent across all MR methods employed (Fig 4 and Supplementary Fig 5). There was 127 evidence of heterogeneity among the individual SNP effect estimates for lifetime smoking with a large Cochran Q statistic (156.18, p=0.02) and MR-PRESSO global test estimate of 128 129 158.4895, p=0.03. However, this was not supported by the symmetrical funnel plot 130 (Supplementary Fig 6) nor by any outliers detected in the MR-PRESSO test. Furthermore, the 131 small MR Egger intercept (-0.003, p=0.69) and consistent MR Egger estimate (OR 1.34, 95% 132 CI 0.49 to 3.65) suggests that the magnitude of potential bias from directional pleiotropy is 133 low. Furthermore, there was no single SNP driving the association whose effect is being 134 masked in the overall estimate as demonstrated by the leave-one-out and single SNP 135 sensitivity analyses (Supplementary Fig 7 and 8). MR excluding the lifetime smoking 136 associated variant located within the MHC region yielded consistent results overlapping the 137 null (Supplementary Table 4).

138 Figure 4: Two-sample Mendelian Randomization estimates of the association between

- 139 lifetime smoking and incidence of multiple sclerosis. Odds ratios are expressed per 1
- standard deviation increase of the lifetime smoking index. MR: Mendelian Randomization;

141 OR=Odds Ratio; CI=Confidence Intervals; p.val: p value.

A bidirectional analysis shows that there was no clear evidence that a genetic predisposition to MS is associated with either smoking initiation or lifetime smoking (Supplementary Table 5 and 7). MR of MS associated variants located within the MHC region yielded consistent results overlapping the null (Supplementary Table 6 and 8).

147

148 **Discussion**

149 This study uses the MR method to estimate the causal effect of smoking on risk for MS.

Using a two-sample MR design in 14,802 MS cases and 26,703 controls, we found little

evidence that both genetically predicted smoking initiation and lifetime smoking are

associated with MS risk. These findings suggest that smoking is not a clear environmental

risk factor for MS susceptibility and are in line with a recent independent study (27).

154 Although a small effect cannot be entirely excluded, the relatively narrow confidence

intervals, particularly for smoking initiation, make a clinically relevant effect less likely.

156 This contradicts previously reported observational studies that show an association with MS

risk among smokers, compared to non-smokers, of a meta-analysed effect estimate odds ratio

of 1.5 (4,11). The studies included limitations such as self-report MS diagnosis (28),

participation rate less than 80% (29–31) and loss to follow up (32). Additionally,

160 observational studies may have heterogenous results due to how smoking status was defined

161 (11). The strength of association and causality between smoking and MS risk has been

suggested due to a dose-dependent relationship in duration and intensity of smoking (4,33) as

163 well as from the interaction between compounds present in cigarettes and specific genetic

164 HLA variants, which include the presence of HLA-DRB1*15, the absence of HLA-A*0201

165 (34) and specific N-acetyltranferase 1 (NAT1) polymorphisms (35). These genetic variants

166 facilitated epitope cross-reactivity and activation of T cells and smoking may strongly

167	influence the risk of MS observed with these HLA genotypes. However, other studies have
168	failed to replicate this interaction (36,37). In order to test this interaction in an MR casual
169	inference context, a factorial MR design in MS patients with and without those alleles would
170	be required. This was not possible in the present study due to the use of GWAS summary
171	statistics. Observational estimates may have also been biased by residual or unmeasured
172	confounding from factors influencing both smoking status and MS. For example, co-
173	morbidities and socioeconomic status may influence the likelihood of being a smoker and
174	having MS (15,38).

175 Reverse causation could also partly explain the discrepancy between our MR results and 176 observational studies especially as MS onset may occur long before the first clinical 177 symptoms (39). For instance, this prodromal phase is characterized in part by a higher risk of 178 depression and anxiety up to 10 years prior to MS diagnosis (40), and these in turn are 179 associated with a higher rate of smoking. This study sought to reduce bias from confounding 180 and reverse causation by using a MR design given genetic variants are much less associated 181 with confounders than directly measured environmental exposures (41) (here smoking) and 182 genetic variants are fixed over our lifetime ensuring directionality of effect. This is a major 183 strength of this study in establishing causality in the relationship between smoking and MS 184 risk. Additionally, MR reverse direction MR was performed and shows that reverse causation 185 is unlikely to be playing a role. A further strength of this study is the use of robust genetic 186 instruments which are strong predictors of smoking behaviour. Finally, we used multiple MR 187 methods and sensitivity analyses to test for bias from directional horizontal pleiotropy. Our 188 estimates were consistent across these multiple methods, strengthening our conclusions. 189 The current study cannot inform us about the effects of smoking on MS symptom severity, 190 disability or progression of disease. Indeed, smoking shows an association with disease

191 progression, disease activity (new lesions on magnetic resonance imaging (MRI); clinical

192	relapse rates) and brain atropy (15). Observational studies have shown an association				
193	between smoking and progression from relapsing remitting MS to secondary progressive MS				
194	with a dose-response relationship (42-46) as well as a faster rate increasing Expanded				
195	Disability Status Scale (EDSS) (22). However, more research in this area is needed to for a				
196	definitive conclusion of an effect and specific mechanisms of action. As new methods are				
197	being developed to assess disease progression using MR (47), when a GWAS of MS				
198	progression becomes available, future studies should explore the association between				
199	smoking and the different measures of MS progression in a MR framework.				
200	The instrument predicting smoking initiation and lifetime smoking were broadly distinct				
201	(only 9 SNPs overlapping). The measure of lifetime smoking exposure takes into account				
202	smoking status and, among ever smokers, duration, heaviness and cessation. Although our				
203	lifetime smoking instrument captured smoking heaviness in part, however we were unable to				
204	explore whether there was a dose-response relationship between the number of cigarettes				
205	smoked and the likelihood of developing MS given we were unable to stratify the MS GWAS				
206	by smoking status. Most, but not all (30,48,49), evidence to date seems to suggest that there				
207	is a positive correlation between the amount smoked and the severity of illness				
208	(4,31,37,43,50–53). It might be that rather than a causal relationship between smoking and				
209	MS risk, that smoking instead accelerates the disease process in those that would have				
210	already developed MS.				
211	Limitations of this study are, firstly, that although we assessed pleiotropy using MR methods				
212	that account for pleiotropic effects, pleiotropy can only be addressed indirectly, and some				
213	SNPs may relate to MS risk through pathways other than smoking. We did not find evidence				
214	for bias for horizontal pleiotropy using the MR Egger intercept test nor the funnel plots which				
215	did not reveal evidence of directional, or unbalanced, pleiotropy. Secondly, this study was a				

- two-sample MR using MS meta-analysis summary statistics and therefore this does not allow
- 217 for gene-environment interaction or sex stratified analysis.
- In conclusion, we find no clear evidence for a causal effect of smoking on the risk of
- 219 developing MS. Previous observational results may have been due to confounding factors,
- 220 which we have avoided through our analysis. Future research should focus on the effect of
- smoking on the disease course of MS and its effect on progression.

222

223 Methods

224 Genetic instruments for smoking

- 225 Smoking initiation. We used the most recent GWAS of smoking initiation from the GWAS &
- 226 Sequencing Consortium of Alcohol and Nicotine use (GSCAN) consortium which identified
- 227 378 conditionally independent genome-wide significant SNPs in a sample of 1,232,091
- 228 individuals of European ancestry. These genetic variants explain 2% of the variance in
- smoking initiation(25).
- 230 Lifetime smoking. In order to incorporate measures of smoking heaviness without having to
- stratify on smoking status (which is not possible in the two-sample MR context without a
- stratified GWAS of MS), we used the GWAS of lifetime smoking conducted in 462,690
- individuals of European ancestry from the UK Biobank (26). Lifetime smoking is a
- combination of smoking initiation, duration, heaviness and cessation described in detail
- elsewhere (26). This GWAS identified 126 independent genome-wide significant SNPs that
- explain 0.36% of the variance(26).

237 Genetic variants associated with multiple sclerosis

238	Effect estimates and standard errors for smoking associated SNPs on MS susceptibility were
239	obtained from the summary statistics of the discovery cohorts of the latest International
240	Multiple Sclerosis Genetics Consortium (IMSGC) meta-analysis, including 14,802 cases and
241	26,703 controls (54). All details relating to demographic characteristics, MS case
242	ascertainment and eligibility criteria for the meta-analysis can be found in the original
243	publication (54). For SNPs not available in the IMSGC dataset, we identified proxy SNPs in
244	high linkage disequilibrium ($r^2 > 0.8$) using an online tool LDlink
245	[https://ldlink.nci.nih.gov/?tab=ldproxy], giving a total of 371 SNPs for smoking initiation
246	instrument and 125 SNPs for lifetime smoking (Figure 2 and Supplementary Table 1 and 2).
247	
248	Mendelian Randomization analyses
240	A two some lo MD was we dontoken to obtain offect estimates of consticulty and isted an object
249	A two sample MR was undertaken to obtain effect estimates of genetically predicted smoking
250	on MS susceptibility, using both initiation and lifetime proxy measures. MR and sensitivity
251	analyses were performed in R (version 3.5.1) using the TwoSampleMR R package
252	(https://mrcieu.github.io/TwoSampleMR/) (55) with effect estimates compared across five
253	different methods: inverse variance weighted (IVW); MR Egger (56); weighted median (57);
254	weighted mode (58); robust adjusted profile score (RAPS) (59); pleiotropy residual sum and
255	outlier (PRESSO) (60). Given the different assumptions that each of these methods make
256	about the nature of pleiotropy, consistency in the point estimate across the methods
257	strengthens causal evidence (61). The IWV method is the main analysis and the other
258	methods provide sensitivity analyses. Instrumental variable analysis of MR is based on a ratio
259	of the regressions of the genetic instrument-outcome association (weighted smoking
260	associated SNPs with MS from IMSGC) on the genetic instrument-exposure association
261	(smoking associated SNPs with smoking initiation or lifetime smoking in the independent
262	smoking GWASs). For smoking initiation, the odds ratios are expressed per unit increase in

263	log odds of ever smoking regularly (smoking initiation); for lifetime smoking, the odds ratios
264	are expressed per 1 standard deviation increase of the lifetime smoking index.
265	Additional sensitivity analyses were performed in order to formally test for potential
266	violations of MR assumptions. The mean F statistic was calculated as an indicator of
267	instrument strength (a value of >10 indicates a strong instrument) and the Cochran's Q
268	statistic was assessed as a measure of heterogeneity for the IVW method to estimate whether
269	the individual SNP effects of smoking on MS were inconsistent. The MR Egger intercept was
270	assessed to detect directional pleiotropy where the genetic instruments would be influencing
271	MS through another pathway other than smoking. To identify potentially influential SNPs,
272	which could be driven for example by horizontal pleiotropy, we used leave-one-out and
273	single-SNP MR analyses. Additionally, due to the strong genetic signal for MS within the
274	MHC region and high potential for pleiotropy, MR analysis excluding exposure variants
275	located within the extended major histocompatibility (MHC) region was performed (defined
276	as base positions 24,000,000 to 35,000,000 on chromosome 6 [GRCh37].

277

279 **<u>References</u>**

280	1.	O'Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward M, Peters SAE. Smoking
281		as a risk factor for lung cancer in women and men: A systematic review and meta-
282		analysis. Vol. 8, BMJ Open. BMJ Publishing Group; 2018.
283	2.	Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of sudden
284		cardiac death: a systematic review and meta-analysis of prospective studies. Eur J
285		Epidemiol [Internet]. 2018 Jun 7 [cited 2020 Jan 20];33(6):509–21. Available from:
286		http://link.springer.com/10.1007/s10654-017-0351-y
287	3.	George MF, Briggs FBS, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, et al.
288		Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.
289		Neurol Genet [Internet]. 2016 Aug [cited 2017 Mar 28];2(4):e87. Available from:
290		http://www.ncbi.nlm.nih.gov/pubmed/27540591
291	4.	Poorolajal J, Bahrami M, Karami M, Hooshmand E. Effect of smoking on multiple
291 292	4.	Poorolajal J, Bahrami M, Karami M, Hooshmand E. Effect of smoking on multiple sclerosis: A meta-analysis. J Public Heal (United Kingdom). 2017 Jun 1;39(2):312–20.
291 292 293	4. 5.	Poorolajal J, Bahrami M, Karami M, Hooshmand E. Effect of smoking on multiple sclerosis: A meta-analysis. J Public Heal (United Kingdom). 2017 Jun 1;39(2):312–20. Dobson R, Giovannoni G. Multiple sclerosis – a review [Internet]. Vol. 26, European
291 292 293 294	4. 5.	 Poorolajal J, Bahrami M, Karami M, Hooshmand E. Effect of smoking on multiple sclerosis: A meta-analysis. J Public Heal (United Kingdom). 2017 Jun 1;39(2):312–20. Dobson R, Giovannoni G. Multiple sclerosis – a review [Internet]. Vol. 26, European Journal of Neurology. Blackwell Publishing Ltd; 2019 [cited 2020 Mar 31]. p. 27–40.
291 292 293 294 295	4.	Poorolajal J, Bahrami M, Karami M, Hooshmand E. Effect of smoking on multiple sclerosis: A meta-analysis. J Public Heal (United Kingdom). 2017 Jun 1;39(2):312–20. Dobson R, Giovannoni G. Multiple sclerosis – a review [Internet]. Vol. 26, European Journal of Neurology. Blackwell Publishing Ltd; 2019 [cited 2020 Mar 31]. p. 27–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30300457
291 292 293 294 295 296	 4. 5. 6. 	 Poorolajal J, Bahrami M, Karami M, Hooshmand E. Effect of smoking on multiple sclerosis: A meta-analysis. J Public Heal (United Kingdom). 2017 Jun 1;39(2):312–20. Dobson R, Giovannoni G. Multiple sclerosis – a review [Internet]. Vol. 26, European Journal of Neurology. Blackwell Publishing Ltd; 2019 [cited 2020 Mar 31]. p. 27–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30300457 Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis.
291 292 293 294 295 296 297	4.5.6.	 Poorolajal J, Bahrami M, Karami M, Hooshmand E. Effect of smoking on multiple sclerosis: A meta-analysis. J Public Heal (United Kingdom). 2017 Jun 1;39(2):312–20. Dobson R, Giovannoni G. Multiple sclerosis – a review [Internet]. Vol. 26, European Journal of Neurology. Blackwell Publishing Ltd; 2019 [cited 2020 Mar 31]. p. 27–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30300457 Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Prim. 2018 Dec 1;4(1):1–27.
291 292 293 294 295 296 297 298	 4. 5. 6. 7. 	 Poorolajal J, Bahrami M, Karami M, Hooshmand E. Effect of smoking on multiple sclerosis: A meta-analysis. J Public Heal (United Kingdom). 2017 Jun 1;39(2):312–20. Dobson R, Giovannoni G. Multiple sclerosis – a review [Internet]. Vol. 26, European Journal of Neurology. Blackwell Publishing Ltd; 2019 [cited 2020 Mar 31]. p. 27–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30300457 Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Prim. 2018 Dec 1;4(1):1–27. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and
291 292 293 294 295 296 297 298 299	 4. 5. 6. 7. 	 Poorolajal J, Bahrami M, Karami M, Hooshmand E. Effect of smoking on multiple sclerosis: A meta-analysis. J Public Heal (United Kingdom). 2017 Jun 1;39(2):312–20. Dobson R, Giovannoni G. Multiple sclerosis – a review [Internet]. Vol. 26, European Journal of Neurology. Blackwell Publishing Ltd; 2019 [cited 2020 Mar 31]. p. 27–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30300457 Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Prim. 2018 Dec 1;4(1):1–27. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Vol. 13, Nature Reviews Neurology.
291 292 293 294 295 296 297 298 299 300	 4. 5. 6. 7. 	 Poorolajal J, Bahrami M, Karami M, Hooshmand E. Effect of smoking on multiple sclerosis: A meta-analysis. J Public Heal (United Kingdom). 2017 Jun 1;39(2):312–20. Dobson R, Giovannoni G. Multiple sclerosis – a review [Internet]. Vol. 26, European Journal of Neurology. Blackwell Publishing Ltd; 2019 [cited 2020 Mar 31]. p. 27–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30300457 Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Prim. 2018 Dec 1;4(1):1–27. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Vol. 13, Nature Reviews Neurology. Nature Publishing Group; 2016. p. 26–36.

301 8. Gohil K. Multiple sclerosis: Progress, but no cure. Vol. 40, P and T. Medi Media USA

302	Inc; 2015. p	. 604–5.
-----	--------------	----------

303	9.	Kister I, Chamot E, Salter AR, Cutter GR, Bacon TE, Herbert J. Disability in multiple
304		sclerosis: A reference for patients and clinicians. Neurology. 2013 Mar
305		12;80(11):1018–24.
306	10.	Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, et al. Association
307		of British Neurologists: Revised (2015) guidelines for prescribing disease-modifying
308		treatments in multiple sclerosis. Pract Neurol. 2015 Jan 8;15(4):273-9.
309	11.	Degelman ML, Herman KM. Smoking and multiple sclerosis: A systematic review and
310		meta-analysis using the Bradford Hill criteria for causation. Vol. 17, Multiple Sclerosis
311		and Related Disorders. Elsevier B.V.; 2017. p. 207-16.
312	12.	Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzer R, Romme Nielsen B,
313		Søndergaard HB, et al. Smoking reduces circulating CD26 hi CD161 hi MAIT cells in
314		healthy individuals and patients with multiple sclerosis . J Leukoc Biol. 2017
315		May;101(5):1211–20.
316	13.	Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJW,
317		Eklund A, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in
318		human lungs and increases citrullination in BAL cells. Ann Rheum Dis [Internet].
319		2008 Oct [cited 2020 Apr 2];67(10):1488–92. Available from:
320		http://www.ncbi.nlm.nih.gov/pubmed/18413445
321	14.	Odoardi F, Sie C, Streyl K, Ulaganathan VK, Schläger C, Lodygin D, et al. T cells
322		become licensed in the lung to enter the central nervous system. Nature [Internet].
323		2012 Aug 30 [cited 2020 Apr 2];488(7413):675–9. Available from:
324		http://www.ncbi.nlm.nih.gov/pubmed/22914092

- 325 15. Rosso M, Chitnis T. Association between Cigarette Smoking and Multiple Sclerosis: A
- 326 Review [Internet]. Vol. 77, JAMA Neurology. American Medical Association; 2020
- 327 [cited 2020 Apr 2]. p. 245–53. Available from:
- 328 http://www.ncbi.nlm.nih.gov/pubmed/31841592
- 16. Hedström AK, Katsoulis M, Hössjer O, Bomfim IL, Oturai A, Sondergaard HB, et al.
- The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement. Eur J Epidemiol. 2017 Oct 1;32(10):909–19.
- 332 17. Sawcer S, Hellenthal G. The major histocompatibility complex and multiple sclerosis:
- a smoking gun? Brain [Internet]. 2011 Mar [cited 2020 Jan 20];134(3):638–40.
- 334 Available from: https://academic.oup.com/brain/article-
- 335 lookup/doi/10.1093/brain/awq384
- 18. Chen JL, Wei L, Bereczki D, Hans FJ, Otsuka T, Acuff V, et al. Nicotine raises the
- influx of permeable solutes across the rat blood-brain barrier with little or no capillary
- recruitment. J Cereb Blood Flow Metab [Internet]. 1995 Jul 29 [cited 2020 Apr
- 339 2];15(4):687–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7790419
- 19. Philbrick DJ, Hopkins JB, Hill DC, Alexander JC, Thomson RG. Effects of prolonged
- 341 cyanide and thiocyanate feeding in rats. J Toxicol Environ Health. 1979;5(4):579–92.
- 342 20. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when
- exposed to nitric oxide. Ann Neurol [Internet]. 2001 Apr 1 [cited 2020 Apr

344 2];49(4):470–6. Available from: http://doi.wiley.com/10.1002/ana.96

- Wingerchuk DM. Smoking: Effects on multiple sclerosis susceptibility and disease
 progression. Vol. 5, Therapeutic Advances in Neurological Disorders. 2012. p. 13–22.
- 347 22. Heydarpour P, Manouchehrinia A, Beiki O, Mousavi SE, Abdolalizadeh A, Lakeh

- 348 MM, et al. Smoking and worsening disability in multiple sclerosis: A meta-analysis.
- 349 Acta Neurol Scand. 2018 Jul 1;138(1):62–9.
- 23. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
- 351 contribute to understanding environmental determinants of disease?*. Int J Epidemiol
- 352 [Internet]. 2003 Feb [cited 2019 Jan 28];32(1):1–22. Available from:
- 353 https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyg070
- 24. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal
- inference in epidemiological studies. Hum Mol Genet [Internet]. 2014 Sep 15 [cited
- 356 2019 Jan 28];23(R1):R89–98. Available from: https://academic.oup.com/hmg/article-
- 357 lookup/doi/10.1093/hmg/ddu328
- 25. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up
- to 1.2 million individuals yield new insights into the genetic etiology of tobacco and
- alcohol use. Vol. 51, Nature Genetics. Nature Publishing Group; 2019. p. 237–44.
- 361 26. Wootton RE, Richmond RC, Stuijfzand BG, Lawn RB, Sallis HM, Taylor GMJ, et al.
- 362 Evidence for causal effects of lifetime smoking on risk for depression and
- 363 schizophrenia: a Mendelian randomisation study. Psychol Med [Internet]. 2019 Nov 6
- 364 [cited 2020 Jan 20];1–9. Available from:
- 365 http://www.ncbi.nlm.nih.gov/pubmed/31689377
- 366 27. Vandebergh M, Goris A. Smoking and multiple sclerosis risk: a Mendelian
- 367 randomization study. J Neurol [Internet]. 2020 [cited 2020 Jun 22]; Available from:
- 368 https://pubmed.ncbi.nlm.nih.gov/32529581/
- Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis.
 Neurology. 2003 Oct 28;61(8):1122–4.

- 371 29. O'Gorman C, Broadley SA. Smoking and multiple sclerosis: evidence for latitudinal
- and temporal variation. J Neurol. 2014;261(9):1677–83.
- 373 30. Salzer J, Hallmans G, Nyström M, Stenlund H, Wadell G, Sundström P. Smoking as a
 374 risk factor for multiple sclerosis. Mult Scler J. 2013;19(8):1022–7.
- 375 31. Hedström AK, Bäärnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not
- 376 Swedish snuff use, increases the risk of multiple sclerosis. Neurology. 2009 Sep

377 1;73(9):696–701.

378 32. Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of

379 multiple sclerosis. BJOG An Int J Obstet Gynaecol. 1998;105(12):1296–9.

- 380 33. Hedström AK, Olsson T, Alfredsson L. Smoking is a major preventable risk factor for
 381 multiple sclerosis. Mult Scler. 2016 Jul 1;22(8):1021–6.
- 382 34. Hedström AK, Sundqvist E, Bä M, Nordin N, Hillert J, Kockum I, et al. Smoking and
- two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.
- A J Neurol [Internet]. [cited 2020 Apr 28]; Available from:
- 385 https://academic.oup.com/brain/article-abstract/134/3/653/446931
- 386 35. Briggs FBS, Acuna B, Shen L, Ramsay P, Quach H, Bernstein A, et al. Smoking and

risk of multiple sclerosis: Evidence of modification by NAT1 variants. Epidemiology.

- 388 2014;25(4):605–14.
- 389 36. Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sørensen PS, Sellebjerg F, et
- al. Smoking affects the interferon beta treatment response in multiple sclerosis.
- 391 Neurology. 2018 Feb 13;90(7):e593–600.
- 392 37. Simon KC, Van Der Mei IAF, Munger KL, Ponsonby A, Dickinson J, Dwyer T, et al.
 393 Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on

394		multiple sclerosis risk. Neurology. 2010;74(17):1365-71.
395	38.	Wingerchuk DM. Smoking: Effects on multiple sclerosis susceptibility and disease
396		progression. Vol. 5, Therapeutic Advances in Neurological Disorders. SAGE
397		Publications; 2012. p. 13–22.
398	39.	Disanto G, Zecca C, MacLachlan S, Sacco R, Handunnetthi L, Meier UC, et al.
399		Prodromal symptoms of multiple sclerosis in primary care. Ann Neurol [Internet].
400		2018 Jun 1 [cited 2020 Apr 3];83(6):1162–73. Available from:
401		http://www.ncbi.nlm.nih.gov/pubmed/29740872
402	40.	M F, AE T, M G, MR M. The Association of Cigarette Smoking With Depression and
403		Anxiety: A Systematic Review. Nicotine Tob Res. 2017;19(1).
404	41.	Smith GD, Ebrahim S. "Mendelian randomization": Can genetic epidemiology
405		contribute to understanding environmental determinants of disease? Vol. 32,
406		International Journal of Epidemiology. 2003. p. 1-22.
407	42.	Koch M, Van Harten A, Uyttenboogaart M, De Keyser J. Cigarette smoking and
408		progression in multiple sclerosis. Neurology. 2007 Oct;69(15):1515-20.
409	43.	Sundström P, Nyström L. Smoking worsens the prognosis in multiple sclerosis. Mult
410		Scler. 2008;14(8):1031–5.
411	44.	Healy BC, Ali EN, Guttmann CRG, Chitnis T, Glanz BI, Buckle G, et al. Smoking and
412		disease progression in multiple sclerosis. Arch Neurol. 2009 Jul;66(7):858-64.
413	45.	Hernán MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H. Cigarette smoking
414		and the progression of multiple sclerosis. Brain [Internet]. 2005 Jun [cited 2020 Apr
415		3];128(Pt 6):1461–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15758034
416	46.	Roudbari SA, Ansar MM, Yousefzad A. Smoking as a risk factor for development of

417	Secondary Progressi	ve Multiple Scleros	sis: A study in IRAN,	Guilan. J Neurol Sci.
-----	---------------------	---------------------	-----------------------	-----------------------

- 418 2013 Jul 15;330(1–2):52–5.
- 419 47. Paternoster L, Tilling K, Davey Smith G. Genetic epidemiology and Mendelian
- 420 randomization for informing disease therapeutics: Conceptual and methodological
- 421 challenges. Barsh GS, editor. PLOS Genet [Internet]. 2017 Oct 5 [cited 2017 Dec
- 422 12];13(10):e1006944. Available from:
- 423 http://www.ncbi.nlm.nih.gov/pubmed/28981501
- 424 48. Maghzi AH, Etemadifar M, Heshmat-Ghahdarijani K, Moradi V, Nonahal S, Ghorbani
- 425 A, et al. Cigarette smoking and the risk of multiple sclerosis: A sibling case-control
- 426 study in Isfahan, Iran. Neuroepidemiology. 2011 Dec;37(3–4):238–42.
- 427 49. Jafari N, Hoppenbrouwers IA, Hop WCJ, Breteler MMB, Hintzen RQ. Cigarette
 428 smoking and risk of MS in multiplex families. Mult Scler. 2009;15(11):1363–7.
- 429 50. Asadollahi S, Fakhri M, Heidari K, Zandieh A, Vafaee R, Mansouri B. Cigarette
- smoking and associated risk of multiple sclerosis in the Iranian population. J Clin
 Neurosci. 2013 Dec 1;20(12):1747–50.
- 432 51. Hedström AK, Hillert J, Olsson T, Alfredsson L. Smoking and multiple sclerosis
 433 susceptibility. Eur J Epidemiol. 2013 Nov;28(11):867–74.
- Ghadirian P, Dadgostar B, Azani R, Maisonneuve P. A case-control study of the
 association between socio-demographic, lifestyle and medical history factors and
- 436 multiple sclerosis. Can J Public Heal. 2001;92(4):281–5.
- 437 53. Mouhieddine TH, Darwish H, Fawaz L, Yamout B, Tamim H, Khoury SJ. Risk factors
- 438 for multiple sclerosis and associations with anti-EBV antibody titers. Clin Immunol.
- 439 2015 May 1;158(1):59–66.

440	54.	Patsopoulos NA, Baranzini SE, Santaniello A, Shoostari P, Cotsapas C, Wong G, et al.		
441		Multiple sclerosis genomic map implicates peripheral immune cells and microglia in		
442		susceptibility. Science (80-). 2019 Sep 27;365(6460).		
443	55.	Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-		
444		Base platform supports systematic causal inference across the human phenome. Elife		
445		[Internet]. 2018 May 30 [cited 2019 Jan 28];7. Available from:		
446		https://elifesciences.org/articles/34408		
447	56.	Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid		
448		instruments: effect estimation and bias detection through Egger regression. Int J		
449		Epidemiol [Internet]. 2015 Apr 1 [cited 2019 Jan 28];44(2):512–25. Available from:		
450		https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/dyv080		
451	57.	Bowden J, Smith GD, Haycock PC, Burgess S. Consistent Estimation in Mendelian		
452		Randomization with Some Invalid Instruments Using a Weighted Median Estimator.		
453		Genet Epidemiol [Internet]. 2016 [cited 2018 Nov 16];40:304–14. Available from:		
454		https://onlinelibrary.wiley.com/doi/pdf/10.1002/gepi.21965		
455	58.	Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian		
456		randomization via the zero modal pleiotropy assumption. Int J Epidemiol [Internet].		
457		2017 Dec 1 [cited 2019 Jan 28];46(6):1985–98. Available from:		
458		https://academic.oup.com/ije/article/46/6/1985/3957932		
459	59.	Zhao Q, Wang J, Hemani G, Bowden J, Small DS. Statistical inference in two-sample		
460		summary-data Mendelian randomization using robust adjusted profile score. 2018 Jan		
461		29 [cited 2020 Jan 23]; Available from: http://arxiv.org/abs/1801.09652		
462	60.	Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy		
463		in causal relationships inferred from Mendelian randomization between complex traits		

- 464 and diseases. Nat Genet [Internet]. 2018 May 23 [cited 2019 Jan 28];50(5):693–8.
- 465 Available from: http://www.nature.com/articles/s41588-018-0099-7
- 466 61. Lawlor DA, Tilling K, Smith GD. Triangulation in aetiological epidemiology. Int J
- 467 Epidemiol. 2016 Dec 1;45(6):1866–86.
- 468
- 469
- 470







MR method	OR	CI	p.val	
Inverse variance weighted		1.03	[0.92, 1.16]	0.60
MR Egger		— 1.13	[0.67, 1.91]	0.65
Weighted median		1.09	[0.94, 1.26]	0.27
Weighted mode		1.15	[0.81, 1.64]	0.44
Robust adjusted profile score (RAPS)		1.05	[0.93, 1.17]	0.42
	0.50 1.0 1.5 Odds Ratio (95% Confidence interv	2.0 /als)		